Oita University

Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor

Retrieved on: 
Friday, December 29, 2023
CSF, Alzheimer's Research & Therapy, Alzheimer's disease, Dementia, Learning, Cerebrospinal fluid, Woman, Elastic net regularization, Heart rate, Sleep, Support vector machine, Hypertension, PET, Disease, Diabetes, Thyroid disease, Brain, Ageing, Risk, Stroke, Oita University, Faculty, Speech, Associate professor, Amyloid beta, Biomarker, Machine learning, Future Development, Manuscript, Transport, Patient, Medical school, Cardiovascular disease, MCI, AUC, Social isolation, Eisai, Area, Exercise, Medical imaging

TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (Aβ) accumulation in the brain using a wristband sensor.

Key Points: 
  • TOKYO, Dec 29, 2023 - (JCN Newswire) - Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta*1 (Aβ) accumulation in the brain using a wristband sensor.
  • This model is expected to enable screening for brain Aβ accumulation, which is an important pathological factor of Alzheimer's disease*2 (AD), simply by collecting biological and lifestyle data from daily life.
  • The key to maximizing treatment effects of the medicine is detecting Abeta accumulation in the brain of patients with mild cognitive impairment before the onset of symptoms.
  • This machine learning model is able to predict brain Aβ accumulation using readily available non-invasive variables.

To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research

Retrieved on: 
Tuesday, November 22, 2022
Cosmos, Amyloid, Self-assessment, Dementia, Diagnosis, PET, Oita University, Attention, MCI, Blood, Ministry, Brain, Physician, AD, Patient, Scientific method, Faculty, Medical school, Cerebrospinal fluid, Department of Neurology, Xuanwu hospital, Shimadzu, Research, Ecosystem, Memory, Amyloid beta, Ministry of Health, Labour and Welfare, CSF, Medical imaging, Health, Eisai, Alzheimer's disease, Neurology, Medicine

This joint study will attempt to develop Japan's first diagnostic workflow for mild cognitive impairment (MCI) and Alzheimer's disease (AD) that uses blood biomarkers.

Key Points: 
  • This joint study will attempt to develop Japan's first diagnostic workflow for mild cognitive impairment (MCI) and Alzheimer's disease (AD) that uses blood biomarkers.
  • Usuki City Medical Association will recruit applicants (50 years and older) who wish to participate in the study.
  • Primary care physicians affiliated with Usuki City Medical Association will perform simple cognitive function tests on applicants and select around 200 people with suspected MCI or mild dementia.
  • With this joint research, the four parties aim to establish a new diagnostic workflow for Alzheimer's disease that is based on blood biomarkers and includes primary care physicians.